Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Katarzyna Śladowska"'
Publikováno v:
Frontiers in Pharmacology, Vol 14 (2023)
Objective: This study aimed to compare the safety profile of tyrosine kinase inhibitors (TKIs) approved for use as monotherapy or combination therapy for the first-line treatment of adult patients with metastatic clear cell renal cell carcinoma (RCC)
Externí odkaz:
https://doaj.org/article/3f37734c92624b33aa2f692b3931e52b
Publikováno v:
Biomedicines, Vol 11, Iss 10, p 2636 (2023)
Major depressive disorder is one of the most severe mental disorders. It strongly impairs daily functioning, and, in extreme cases, it can lead to suicide. Although different treatment options are available for patients with depression, there is an o
Externí odkaz:
https://doaj.org/article/ee1579b6c7704f01b7440ca0560e0bdc
Publikováno v:
Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 43(9)
This study aimed to compare the safety profile of high-efficacy disease-modifying therapies (DMTs) natalizumab, fingolimod, alemtuzumab, cladribine, ocrelizumab, ofatumumab, ozanimod, as well as a potentially high-efficacy DMT, ponesimod, in adult pa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e29966d7336d663569d615ac9bfdd0c5
https://pubmed.ncbi.nlm.nih.gov/35713731
https://pubmed.ncbi.nlm.nih.gov/35713731
Publikováno v:
Therapeutics and Clinical Risk Management
Xeljanz® (tofacitinib) is an oral small-molecule inhibitor that reversibly inhibits Janus-activated kinase (JAK)-dependent cytokine signaling, thus reducing inflammation. As a result of these mechanisms, effects on the immune system such as a modera
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8521dfca0e1ee426f4ee11f8f8e7dba3
https://doi.org/10.2147/tcrm.s138677
https://doi.org/10.2147/tcrm.s138677
Autor:
Paweł, Kawalec, Katarzyna, Śladowska, Iwona, Malinowska-Lipień, Tomasz, Brzostek, Maria, Kózka
Publikováno v:
Therapeutics and Clinical Risk Management
Baricitinib is an innovative small-molecule drug that reversibly inhibits continuous activation of JAK/STAT pathway, thus reducing joint inflammation. The drug was approved for use as monotherapy or in combination with methotrexate (MTX) in the treat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::0a510b46ec75fada9965efc0ad65373d
https://pubmed.ncbi.nlm.nih.gov/30858707
https://pubmed.ncbi.nlm.nih.gov/30858707
Autor:
Irena Oszczapowicz, Urszula Kłaput, Barbara Janota, Katarzyna Śladowska, Lidia Mazur, Małgorzata Opydo-Chanek, Małgorzata Łukawska
Publikováno v:
Anticancer Research. 37
Background/aim Epidoxorubicin is an anthracycline agent. The present study was undertaken to compare the antileukemic potential of epidoxorubicin and its two formamidine analogs containing either a morpholine moiety (EPIFmor) or a hexamethyleneimine
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e8e007713eb1bcf2e799afcea5788a71
https://doi.org/10.21873/anticanres.12089
https://doi.org/10.21873/anticanres.12089
Autor:
Katarzyna Śladowska, Katarzyna Kieć-Kononowicz, Ewa Trybus, T. Krol, Małgorzata Opydo-Chanek, Anna Kopacz-Bednarska, Jadwiga Handzlik, Wojciech Trybus, Lidia Mazur
Publikováno v:
Anticancer Research. 37
BACKGROUND/AIM To search for new antileukemic agents, the chemical structure of phenytoin was modified. A possible cytotoxic activity of three bromoalkyl phenytoin analogs, methyl 2-(1-(3-bromopropyl)-2,4-dioxo-5,5-diphenylimidazolidin-3-yl) propanoa
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::30def2a98a918a6f73dfd8372ea84216
https://doi.org/10.21873/anticanres.12090
https://doi.org/10.21873/anticanres.12090
Autor:
Katarzyna Śladowska, Ulf Niemeyer, Kamil Blicharski, Peter Fedoročko, Małgorzata Opydo-Chanek, Jaromír Mikeš, Lidia Mazur
Publikováno v:
ResearcherID
Background/aim The oxazaphosphorines, ifosfamide and cyclophosphamide, represent a class of alkylating agents. The aim of the present in vitro study was to compare antileukemic activity of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophos
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5897c18ffedbb746b1bcc1fc016574ed
https://doi.org/10.21873/anticanres.12088
https://doi.org/10.21873/anticanres.12088
Autor:
Malgorzata, Opydo-Chanek, Katarzyna, Śladowska, Kamil, Blicharski, Jaromir, Mikeš, Peter, Fedoročko, Ulf, Niemeyer, Lidia, Mazur
Publikováno v:
Anticancer research. 37(11)
The oxazaphosphorines, ifosfamide and cyclophosphamide, represent a class of alkylating agents. The aim of the present in vitro study was to compare antileukemic activity of 4-hydroperoxyifosfamide (4-OOH-IF) and 4-hydroperoxycyclophosphamide (4-OOH-
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::3fc56f368fe83a80dfe7f5697331302a
https://pubmed.ncbi.nlm.nih.gov/29061820
https://pubmed.ncbi.nlm.nih.gov/29061820
Publikováno v:
Indian journal of experimental biology. 54(9)
Hydantoin derivatives, including phenytoin (5,5-diphenylhydantoin), have recently gained attention as they possess a variety of important biochemical and pharmacological properties. Nevertheless, available information on anticancer activity of hydant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::9622340201a382ebe16096f88aeb542c
https://pubmed.ncbi.nlm.nih.gov/28699720
https://pubmed.ncbi.nlm.nih.gov/28699720